Tag: agios pharmaceuticals

November 13, 2019

Agios Pharmaceuticals Closes Public Offering

The company has additionally announced the option for its underwriters to purchase an additional 1.23 million shares at US$31 each.
January 1, 2019

An Investor’s Guide to Clinical Trials

Clinical trials can be one of the more challenging US Food and Drug Administration processes to understand, but grasping the...
December 3, 2018

Agios Presents Updated Data from the Ivosidenib Phase 1 Dose-Escalation and Expansion Trial

Agios Pharmaceuticals (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today presented...
November 16, 2018

Agios Presents Updated Data from Phase 1 Dose-Escalation Study of AG-881 in Patients with IDH Mutant Positive Advanced Glioma

Agios Pharmaceuticals (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today presented...
July 20, 2018

FDA Grants Approval of Agios’ Pharmaceuticals’ TIBSOVO®

Agios Pharmaceuticals (NASDAQ:AGIO) has announced that TIBSOVO was granted approval from the US Food and Drug Administration (FDA) for treatment...
June 26, 2018

Agios and CStone Pharmaceuticals Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Ivosidenib in Greater China

Agios Pharmaceuticals (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, and CStone...